Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis

Gul Shahnaz, Benson J. Edagwa, Joellyn McMillan, Sohail Akhtar, Abida Raza, Naveeda A. Qureshi, Masoom Yasinzai, Howard E. Gendelman

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


Aim: Our goal was to improve treatment outcomes for visceral leishmaniasis by designing nanocarriers that improve drug biodistribution and half-life. Thus, long-acting mannose-anchored thiolated chitosan amphotericin B nanocarrier complexes (MTC AmB) were developed and characterized. Materials & methods: A mannose-anchored thiolated chitosan nanocarrier was manufactured and characterized. MTC AmB was examined for cytotoxicity, biocompatibility, uptake and antimicrobial activities. Results: MTC AmB was rod shaped with a size of 362 nm. MTC AmB elicited 90% macrophage viability and 71-fold enhancement in drug uptake compared with native drug. The antileishmanial IC50 for MTC AmB was 0.02 μg/ml compared with 0.26 μg/ml for native drug. Conclusion: These studies show that MTC can serve as a platform for clearance of Leishmania in macrophages.

Original languageEnglish (US)
Pages (from-to)99-115
Number of pages17
Issue number2
StatePublished - Jan 2017


  • amphotericin B
  • macrophage nanoparticle targeting
  • mannose receptors
  • thiolated chitosan
  • visceral leishmaniasis

ASJC Scopus subject areas

  • Bioengineering
  • Development
  • Biomedical Engineering
  • General Materials Science
  • Medicine (miscellaneous)


Dive into the research topics of 'Development of mannose-anchored thiolated amphotericin B nanocarriers for treatment of visceral leishmaniasis'. Together they form a unique fingerprint.

Cite this